Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription.
Major histocompatibility complex class I (MHC I) molecules present antigenic peptides for CD8(+) T-cell recognition. Prior to cell surface expression, proper MHC I loading is conducted by the peptide-loading complex (PLC), composed of the MHC I heavy chain (HC) and β(2)-microglobulin (β(2)m), the peptide transporter TAP, and several chaperones, including tapasin. Tapasin connects peptide-receptive MHC I molecules to the PLC, thereby facilitating loading of high-affinity peptides onto MHC I. To cope with CD8(+) T-cell responses, human cytomegalovirus (HCMV) encodes several posttranslational strategies inhibiting peptide transport and MHC I biogenesis which have been studied extensively in transfected cells. Here we analyzed assembly of the PLC in naturally HCMV-infected fibroblasts throughout the protracted replication cycle. MHC I incorporation into the PLC was absent early in HCMV infection. Subsequently, tapasin neosynthesis became strongly reduced, while tapasin steady-state levels diminished only slowly in infected cells, revealing a blocked synthesis rather than degradation. Tapasin mRNA levels were continuously downregulated during infection, while tapasin transcripts remained stable and long-lived. Taking advantage of a novel method by which de novo transcribed RNA is selectively labeled and analyzed, an immediate decline of tapasin transcription was seen, followed by downregulation of TAP2 and TAP1 gene expression. However, upon forced expression of tapasin in HCMV-infected cells, repair of MHC I incorporation into the PLC was relatively inefficient, suggesting an additional level of HCMV interference. The data presented here document a two-pronged coordinated attack on tapasin function by HCMV.
Institute for Virology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Anne
A
Halenius
Sebastian
S
Hauka
Lars
L
Dölken
Jan
J
Stindt
Henrike
H
Reinhard
Constanze
C
Wiek
Helmut
H
Hanenberg
Ulrich H
UH
Koszinowski
Frank
F
Momburg
Hartmut
H
Hengel
D017951:Antigen Presentation; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000276:immunology / Q000472:pathogenicity*; D005347:Fibroblasts / Q000821:virology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D057131:Immune Evasion; D026901:Membrane Transport Proteins / Q000096:biosynthesis*; D014158:Transcription, Genetic
D015395:Histocompatibility Antigens Class I; D026901:Membrane Transport Proteins; C107762:tapasin
Curr Opin Immunol. 1997 Aug;9(4):470-6
9287180
Immunity. 1994 Sep;1(6):491-500
7895159
Nat Immunol. 2007 Aug;8(8):873-81
17603487
Gene. 1995 May 26;158(1):9-14
7789817
J Exp Med. 2010 Aug 30;207(9):2033-41
20713594
Proc Natl Acad Sci U S A. 1990 Jul;87(13):5183-7
2164225
Blood. 2006 May 1;107(9):3624-31
16384928
Science. 2007 Jul 20;317(5836):376-81
17641203
J Virol. 1991 Dec;65(12):6724-34
1658371
EMBO J. 1998 Apr 15;17(8):2186-95
9545232
Immunity. 2002 Apr;16(4):509-20
11970875
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10990-5
8855296
Virology. 2007 Oct 25;367(2):334-8
17590404
J Cell Sci. 2010 Dec 15;123(Pt 24):4271-9
21098634
Traffic. 2000 Apr;1(4):318-25
11208117
J Virol. 2002 Sep;76(17):8596-608
12163579
Nat Rev Immunol. 2009 Jul;9(7):503-13
19498380
EMBO J. 1999 Feb 1;18(3):743-53
9927434
Nature. 1991 Dec 19-26;354(6354):528-31
1758495
J Virol. 1999 Oct;73(10):8320-9
10482582
Immunology. 2005 Mar;114(3):346-53
15720436
J Virol. 1995 Aug;69(8):4830-41
7609050
J Virol. 2006 Jan;80(2):951-63
16378997
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11737-42
15286279
Immunol Lett. 2002 Oct 1;83(3):197-207
12095710
J Biol Chem. 1997 Jun 27;272(26):16585-90
9195970
Immunogenetics. 2003 Sep;55(6):379-88
12942211
EMBO J. 2005 Oct 19;24(20):3613-23
16193070
Cell. 2006 Oct 20;127(2):369-82
17055437
J Exp Med. 2002 Sep 16;196(6):805-16
12235213
Nature. 1996 Dec 5;384(6608):432-8
8945469
Immunity. 1997 May;6(5):613-21
9175839
J Immunol. 2002 Feb 15;168(4):1950-60
11823531
J Mol Biol. 1998 Apr 10;277(4):839-57
9545376
EMBO J. 2009 Dec 2;28(23):3730-44
19851281
J Biol Chem. 2006 Mar 3;281(9):5383-90
16356928
J Gen Virol. 2008 Oct;89(Pt 10):2416-2426
18796709
J Biol Chem. 2006 Apr 21;281(16):11135-43
16473883
J Virol. 2002 Nov;76(22):11753-6
12388737
FEBS Lett. 1994 Sep 12;351(3):443-7
8082812
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10477-82
18650385
J Biol Chem. 2002 May 24;277(21):18266-71
11884415
J Virol. 2001 Nov;75(22):11218-21
11602761
RNA. 2008 Sep;14(9):1959-72
18658122
J Virol. 1996 Nov;70(11):7569-79
8892876
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6904-9
9192664
J Virol. 1997 Apr;71(4):2970-9
9060656
Immunity. 1996 Aug;5(2):103-14
8769474
J Immunol. 2007 Dec 1;179(11):7614-23
18025207
Immunity. 2004 Jan;20(1):71-85
14738766
J Virol. 1999 Oct;73(10):8179-84
10482568
J Gen Virol. 1996 Sep;77 ( Pt 9):2287-96
8811029
J Immunol. 2010 Jan 1;184(1):73-83
19949070
J Gen Virol. 1995 Dec;76 ( Pt 12):2987-97
8847504
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11327-33
8876135
Mol Immunol. 2009 Jun;46(10):2054-63
19362740
Cell. 1996 Mar 8;84(5):769-79
8625414
J Virol. 2002 Jul;76(13):6832-5
12050396
Immunity. 1997 May;6(5):623-32
9175840